Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Hao, Yaping ^a   Zhou, Jian ^a   Zhou, Mi ^a   Ma, Xiaojing ^a   Lu, Zhigang ^a   Gao, Meifang ^a   Pan, Xiaoping ^a   Tang, Junling ^a   Bao, Yuqian ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 19; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 84881349710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072345     Document Type: Article

References (24)

1. Lundåsen T, Gälman C, Angelin B, Rudling M, (2006) Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260: 530-536.
2. Song KH, Li T, Owsley E, Strom S, Chiang JY, (2009) Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49: 297-305.
3. Wu X, Li Y, (2011) Therapeutic utilities of fibroblast growth factor 19. Expert Opin Ther Targets 15: 1307-1316.
4. Wu X, Li Y, (2012) Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. Adv Exp Med Biol 728: 195-213.
5. Tomlinson E, Fu L, John L, Hultgren B, Huang X, et al. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747.
6. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603.
7. Stejskal D, Karpísek M, Hanulová Z, Stejskal P, (2008) Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 68: 501-507.
8. Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, et al. (2011) Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. Physiol Res 60: 627-636.
9. Eren F, Kurt R, Ermis F, Atug O, Imeryuz N, et al. (2012) Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 45: 655-658.
10. Gensini GG, (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51: 606.
11. Judkins MP, (1968) Percutaneous transfemoral selective coronary arteriography. Radiol Clin North Am 6: 467-492.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
13. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, et al. (2011) Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 41: 390-396.
14. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ, (2001) Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291: 2613-2616.
15. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, et al. (2002) Loss of stearoyl-CoA desaturaserase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99: 11482-11486.
16. Strack AM, Myers RW, (2004) Modulation of Metabolic Syndrome by Fibroblast Growth Factor 19 (FGF19)? Endocrinology 145: 2591-2593.
17. Bhatnagar S, Damron HA, Hillgartner FB, (2009) Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 284: 10023-10033.
18. Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, et al. (2010) Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42: 178-181.
19. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935.
20. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461-2468.
21. Parul SS, Mazumder M, Debnath BC, Haque ME, (2011) Serum adiponectin in patients with coronary heart disease. Mymensingh Med J 20: 78-82.
22. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, et al. (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92: 571-576.
23. Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, et al. (2007) Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 193:: 1787-451. Circulation 2008, 117: 1787-1801
24. Soubassi LP, Chiras TC, Papadakis ED, Poulos GD, Chaniotis DI, et al. (2006) Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol 38: 795-800.